Oxford Astrazeneca Covid Vaccine
- All
- News
- Videos
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
AstraZeneca Tests Booster Vaccine Against Beta Variant Of Covid
AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.
-
How to Download COVID-19 Vaccine Certificate
There are two COVID-19 vaccines currently in use in India. Covaxin is made by Bharat Biotech and Covishield is made by AstraZeneca/ Oxford and manufactured by the Serum Institute of India. Here’s how to download the COVID-19 vaccination certificate after both the shots have been administered.
-
Covishield Comprises Over 90% Of 12.76 Crore Covid Vaccines Given So Far: Government Data
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday.
-
Italy To Restart AstraZeneca Vaccinations From Friday, Says PM
Italy will resume administering AstraZeneca/Oxford coronavirus vaccines on Friday after the EU's drugs regulator declared them safe, Prime Minister Mario Draghi said.
-
Germany To Recommend Oxford Covid Vaccine For Over 65s: Angela Merkel
Germany will soon authorise the AstraZeneca/Oxford vaccine against Covid for people over the age of 65, Chancellor Angela Merkel said Wednesday.
-
Sri Lanka May Not Use China Vaccine, Orders 13.5 Million Doses From India
Sri Lanka has ordered 13.5 million Oxford AstraZeneca coronavirus vaccines in addition to the 500,000 doses gifted by India, and the country may not use Chinese vaccines in the second phase of immunisation, a government spokesman said today.
-
Will Send Covid Vaccine To Canada In "Less Than A Month": Serum Institute
The Serum Institute of India will ship the Oxford University/AstraZeneca COVID-19 vaccine to Canada in less than one month, Serum's chief executive said on Monday.
-
Oxford Covid Vaccine To Be Tested On Children For First Time
The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
-
Oxford Covid Vaccine Less Effective Against South African Variant: Study
British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
AstraZeneca Tests Booster Vaccine Against Beta Variant Of Covid
AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.
-
How to Download COVID-19 Vaccine Certificate
There are two COVID-19 vaccines currently in use in India. Covaxin is made by Bharat Biotech and Covishield is made by AstraZeneca/ Oxford and manufactured by the Serum Institute of India. Here’s how to download the COVID-19 vaccination certificate after both the shots have been administered.
-
Covishield Comprises Over 90% Of 12.76 Crore Covid Vaccines Given So Far: Government Data
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday.
-
Italy To Restart AstraZeneca Vaccinations From Friday, Says PM
Italy will resume administering AstraZeneca/Oxford coronavirus vaccines on Friday after the EU's drugs regulator declared them safe, Prime Minister Mario Draghi said.
-
Germany To Recommend Oxford Covid Vaccine For Over 65s: Angela Merkel
Germany will soon authorise the AstraZeneca/Oxford vaccine against Covid for people over the age of 65, Chancellor Angela Merkel said Wednesday.
-
Sri Lanka May Not Use China Vaccine, Orders 13.5 Million Doses From India
Sri Lanka has ordered 13.5 million Oxford AstraZeneca coronavirus vaccines in addition to the 500,000 doses gifted by India, and the country may not use Chinese vaccines in the second phase of immunisation, a government spokesman said today.
-
Will Send Covid Vaccine To Canada In "Less Than A Month": Serum Institute
The Serum Institute of India will ship the Oxford University/AstraZeneca COVID-19 vaccine to Canada in less than one month, Serum's chief executive said on Monday.
-
Oxford Covid Vaccine To Be Tested On Children For First Time
The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
-
Oxford Covid Vaccine Less Effective Against South African Variant: Study
British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
